Avid Bioservices Adds Single-Use Bioreactors to Expand Manufacturing in California

May 1, 2017

Avid, a wholly owned subsidiary of Peregrine Pharmaceuticals, will upgrade its Myford, California clinical and commercial manufacturing facility with multiple Mobius 2000-L single-use bioreactors from MilliporeSigma, the companies announced on May 1, 2017.

Avid, a wholly owned subsidiary of Peregrine Pharmaceuticals, will upgrade its Myford, California clinical and commercial manufacturing facility with multiple Mobius 2000-L single-use bioreactors from MilliporeSigma, the companies announced on May 1, 2017.

“Adding the Mobius technology to expand Avid’s Myford biomanufacturing capacity highlights our commitment to offer customers the latest single-use equipment and flexible solutions,” said Steven W. King, president, Avid Bioservices, in a press release. The first 2000-L pilot batch is planned for later this month.

“The planned installation of MilliporeSigma’s Mobius 2000-liter bioreactors opens new opportunities for current and future Avid customers who require greater manufacturing capacity,” King added. “We have already secured customer commitments for the 2000-liter capacity as soon as it is installed in our Myford facility and believe the advanced technology it offers will be a key factor in continuing to grow our contract development and manufacturing organization business.”

Avid has installed the appropriate systems at its Myford facility to allow integration of MilliporeSigma’s Mobius bioreactors. The 40,000-ft2 facility was designed to accommodate a fully disposable biomanufacturing process for late Phase III clinical and commercial biologics production. The facility can operate multiple bioreactors simultaneously, improving manufacturing capacity and efficiency.

Sources: MilliporeSigma and Avid Bioservices